RxDoctor Payments Data

Dennis Oleary, DO

Internal Medicine · N Miami Beach, FLNPI 1851464671

Payments from drug & device makers

$1,408in general payments, 2019–2025

Across 78 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$305
  • Novo Nordisk$287
  • AstraZeneca$277
  • Sanofi-aventis U.S. LLC$109
  • Pfizer$106
  • Amgen$87
  • plus $238 from 9 others

What the payments were for

  • Food & beverage$1,37598%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,408 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$37,923
Medicare patients
67
Services billed
657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$68,759
JardianceEmpagliflozin34$23,457
XareltoRivaroxaban34$20,538
ProliaDenosumab11$19,300
RybelsusSemaglutide14$18,348
FarxigaDapagliflozin Propanediol17$9,476
TresibaInsulin Degludec15$7,773
Tresiba Flextouch U-100Insulin Degludec18$7,186
TradjentaLinagliptin12$6,055
SymbicortBudesonide/Formoterol Fumarate26$5,782
Breo ElliptaFluticasone/Vilanterol15$5,017
Advair HfaFluticasone Propion/Salmeterol12$4,496
Atorvastatin Calcium478$3,730
LantusInsulin Glargine,hum.Rec.Anlog33$3,478
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$2,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$106$68,75983 claims
Boehringer IngelheimJardiance, Tradjenta$23$29,51246 claims
Novo NordiskRybelsus, Tresiba$287$26,12229 claims
Johnson & JohnsonXarelto$15$20,53834 claims
AmgenProlia$87$19,30011 claims
AstraZenecaFarxiga, Symbicort$277$15,25843 claims
GSKBreo Ellipta$305$5,01715 claims
Sanofi-aventis U.S. LLCLantus$109$3,47833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in N Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →